Related by context. All words. (Click for frequent words.) 73 progression TTP 71 imatinib therapy 71 relapsed MM 71 biochemical relapse 70 FOLFOX4 70 pegylated liposomal doxorubicin 70 Subgroup analysis 70 PSADT 70 Platinol ® 69 tumor progression TTP 69 morphometric vertebral fractures 69 Pemetrexed 69 interferon ribavirin 69 FOLFIRI 69 carboplatin paclitaxel 69 pyridostigmine 69 gemcitabine carboplatin 68 MGd 68 activated partial thromboplastin 68 plus prednisone 68 Xelox 68 sorafenib Nexavar 68 radiotherapy RT 68 VELCADE melphalan 68 recurrent glioblastoma multiforme 68 Doxil ® 68 metastatic malignant 68 liver histology 68 paricalcitol 68 rosuvastatin #mg 68 EGFR TKI 68 docetaxel chemotherapy 68 peg interferon 68 salmeterol fluticasone 68 Peg IFN 67 5FU 67 posttransplant 67 plasma uric acid 67 adalimumab Humira 67 temsirolimus 67 Telintra 67 irinotecan chemotherapy 67 ribavirin RBV 67 doxorubicin docetaxel 67 paclitaxel poliglumex 67 gefitinib Iressa 67 PEG IFN 67 rindopepimut 67 complete cytogenetic response 67 intravenous cyclophosphamide 67 FUSILEV enhances 67 mg/m2 dose 67 MAGE A3 ASCI 67 trastuzumab Herceptin ® 67 disease progression TTP 67 Kaplan Meier analysis 67 CIMZIA TM certolizumab pegol 67 androgen suppression 67 chemoradiotherapy 67 CTEPH 67 estramustine 67 5-fluorouracil/leucovorin 67 APTIVUS r 67 tipranavir r 67 5-FU/LV 67 mycophenolate mofetil 67 Vidaza azacitidine 67 CCyR 67 postoperative chemotherapy 67 pertuzumab 67 plus prednisone prednisolone 67 irbesartan 67 octreotide LAR 66 docetaxel Taxotere ® 66 aPTT 66 zonisamide SR 66 adriamycin 66 standard chemotherapy regimen 66 tumor necrosis 66 NMIBC 66 mg kg dose 66 mRCC 66 intermittent dosing 66 verteporfin 66 Flu Cy 66 nicardipine 66 severe oral mucositis 66 tipifarnib 66 FOLPI 66 Thal Dex 66 melphalan prednisone 66 alfa 2a 66 mapatumumab 66 CR nPR 66 plasma kallikrein inhibitor 66 ZOLINZA 66 KRAS mutations occur 66 leukemia AML 66 locoregional disease 66 DOXIL 66 PegIFN RBV 66 gemcitabine Gemzar ® 66 symptomatic VTE 66 pomalidomide 66 androgen deprivation 66 fluvastatin 66 azacitidine 66 Aflibercept 66 gemcitabine cisplatin 66 cisplatin vinorelbine 66 comparator arm 66 lumbar spine BMD 66 DAPT 66 EFAPROXYN 66 Bosentan 66 intravesical therapy 66 cisplatin chemotherapy 66 ABVD 66 abacavir lamivudine 66 plus dexamethasone 66 FOLFOX6 66 ritonavir boosted 66 prior chemotherapy regimens 66 gemcitabine Gemzar 66 fibrinolysis 66 Bezielle 65 FOLFOX6 chemotherapy regimen 65 ribavirin USP 65 somatostatin analog 65 serum phosphate 65 mitoxantrone plus 65 genotypic resistance 65 GOUT 65 olmesartan 65 certolizumab 65 idarubicin 65 chemoradiation therapy 65 Myelodysplastic Syndrome MDS 65 prednisone prednisolone 65 antithymocyte globulin 65 NATRECOR ® 65 anti leukemic 65 8mg/kg 65 ancrod 65 #mg BID [001] 65 Kinoid 65 CRp 65 underwent liver transplantation 65 radiographic progression 65 pharmacodynamic PD 65 cancer mCRC 65 Seliciclib 65 eplerenone 65 achieved CCyR 65 pCR 65 idraparinux 65 β blockers 65 Adjuvant chemotherapy 65 Folfox 65 hour bronchodilation 65 CALGB # [002] 65 Free Survival PFS 65 papillary renal cell carcinoma 65 cis retinoic acid 65 thalidomide Thalomid 65 colorectal adenoma 65 recurrent metastatic 65 q#h 65 CR CRu 65 paclitaxel carboplatin 65 Hydroxyurea 65 erlotinib Tarceva ® 65 nab paclitaxel 65 K ras mutations 65 posaconazole 65 CHAMPION PCI 65 corrected QT interval 65 PASI scores 65 peginterferon alfa 2a 65 dosage regimens 65 desvenlafaxine succinate 65 decitabine 65 rFVIIa 65 CIMZIA TM 65 glycated hemoglobin levels 65 glycosylated hemoglobin HbA1c 65 oral clodronate 65 pegylated interferon alfa 2b 65 AGILECT R 65 ® lenalidomide 65 median PFS 65 pegylated interferon peg IFN 65 pharmacodynamics PD 65 neostigmine 65 visceral metastases 65 reinfarction 65 dose dexamethasone 65 CIMZIA ™ 65 bortezomib Velcade R 65 pamidronate 65 neutropenic sepsis 65 % CI #.#-#.# [003] 65 fulvestrant 65 Non inferiority 65 galiximab 65 liposomal doxorubicin 65 PSMA ADC 65 antiangiogenic therapy 65 steroid dexamethasone 65 oblimersen 65 octreotide 65 mitomycin 65 pharmacokinetic characteristics 65 adjuvant cisplatin 65 EGFR mutation positive 65 disease progression 65 peginterferon alpha 2a 65 Kaplan Meier estimate 65 recurrent VTE 65 achieved ACR# 65 overt nephropathy 65 bosentan 65 demonstrated antitumor activity 65 radiochemotherapy 65 lenalidomide dexamethasone 65 AZT zidovudine Retrovir 65 cetuximab Erbitux R 65 chemotherapy gemcitabine 64 #mg QD [001] 64 INCB# [001] 64 recurrent malignant glioma 64 HSCT 64 riociguat 64 ertapenem 64 dosing cohort 64 TLUS 64 heavily pretreated 64 topotecan 64 teriflunomide 64 telaprevir dosed 64 TNF antagonist 64 Temsirolimus 64 secondary efficacy endpoint 64 Teriflunomide 64 Omacetaxine 64 atazanavir ritonavir 64 dalteparin 64 plus MTX 64 prospectively defined 64 low dose cytarabine 64 Torisel 64 IFN α 64 aromatase inhibitor therapy 64 urinary N telopeptide 64 PSA nadir 64 TAXUS VI 64 clodronate 64 mitoxantrone 64 axitinib 64 busulfan 64 KRAS mutant tumors 64 HCV RESPOND 2 64 partial thromboplastin 64 chlorambucil 64 oral rivaroxaban 64 methotrexate therapy 64 STRIDE PD 64 cisplatin gemcitabine 64 Pegylated Interferon 64 metastatic malignant melanoma 64 serum calcium levels 64 vidofludimus 64 peginterferon 64 GAMMAGARD 64 ATACAND 64 ribavirin therapy 64 inotropic 64 radioiodine therapy 64 ELACYT 64 doxorubicin cyclophosphamide 64 HIV HCV coinfected 64 erlotinib Tarceva 64 ANAVEX #-# [001] 64 viral kinetics 64 venlafaxine XR 64 stage IIIb IV 64 CLORETAZINE TM VNP#M 64 lenalidomide Revlimid R 64 corticosteroid dose 64 angiographic outcomes 64 locoregional 64 debulking surgery 64 QTcF 64 Solid Tumors criteria 64 gemcitabine chemotherapy 64 placebo controlled clinical 64 APTIVUS 64 5 Fluorouracil 64 CDK inhibitor 64 INCB# [003] 64 hyperphenylalaninemia HPA due 64 q8h 64 QTc prolongation 64 CYT# potent vascular disrupting 64 Fulvestrant 64 imexon 64 #mg/m# [001] 64 methotrexate monotherapy 64 mutated KRAS 64 Pegylated Liposomal Doxorubicin 64 #mg/m# [002] 64 CHOP chemotherapy 64 locoregional recurrence 64 ara C 64 elevated transaminases 64 cyclophosphamide methotrexate 64 nondiabetic patients 64 graft occlusion 64 Aptivus ® 64 cilengitide 64 paclitaxel Taxol 64 Xanafide 64 #mg/day [002] 64 relapsed ALL 64 fluorouracil 64 trial evaluating PRX# 64 BARACLUDE ® 64 everolimus eluting stents 64 glufosfamide 64 gamma secretase inhibitor 64 bortezomib Velcade 64 beta 1a 64 COPAXONE R 64 Fludarabine 64 FOLFIRI alone 64 CTAP# Capsules 64 crizotinib PF # 64 CANCIDAS 64 antiandrogens 64 virologic response 64 palifermin 64 dasatinib Sprycel 64 flutamide 64 hepatic fibrosis 64 unfractionated heparin UFH 64 otamixaban 64 Cloretazine 64 pharmacodynamic effects 64 LPV r 64 clinically meaningful improvements 64 baminercept 64 Degarelix 64 taxane refractory 64 TTF Therapy 64 5 FU leucovorin 64 surgical debulking 64 weekly subcutaneous injections 64 acute mania 64 severe neutropenia 64 intravascular hemolysis 63 visilizumab 63 taxane resistant 63 p# biomarker 63 pharmacokinetic parameters 63 fosamprenavir 63 #mg QD [002] 63 plus gemcitabine 63 XELOX 63 ischemia induced 63 abiraterone acetate 63 perioperatively 63 catheter occlusion 63 ULORIC 63 androgen ablation 63 paclitaxel cisplatin 63 induce remission 63 DLTs 63 iloprost 63 colesevelam HCl 63 dacarbazine 63 lapatinib Tykerb 63 NATRECOR R 63 dasatinib Sprycel ® 63 mL/min/#.# m 2 63 serum urate levels 63 Peginterferon 63 adjuvant tamoxifen 63 concurrent chemoradiation 63 5 FU 63 inhaled iloprost 63 vandetanib 63 achieved statistical significance 63 sitaxsentan 63 clomipramine 63 virologic 63 adalimumab 63 % CI #.#-#.# [007] 63 timepoints 63 cranial irradiation 63 vorinostat 63 anthracycline taxane 63 recurrent GBM 63 IFN beta 63 liver resection 63 urocortin 2 63 daily subcutaneous injections 63 bolus injection 63 sunitinib Sutent 63 bleomycin 63 systemic ALCL 63 aminotransferase levels 63 Secondary endpoints include 63 postoperative complication 63 oral diclofenac 63 oral deforolimus 63 bolus dose 63 humanised monoclonal antibody 63 fluticasone salmeterol 63 TMC# r 63 zoledronate 63 immunomodulatory therapy 63 relapsed CLL 63 QTc intervals 63 bronchodilation 63 mg administered orally 63 rALLy 63 PREZISTA r 63 clinically meaningful improvement 63 alteplase 63 interferon therapy 63 Gemzar ® 63 potentially hepatotoxic 63 Irinotecan 63 dacarbazine DTIC 63 #mg ATC 63 RE LY ® 63 metastatic hormone refractory 63 plus methotrexate 63 Patency 63 tipranavir 63 Hormone Refractory Prostate Cancer 63 ibandronate 63 mesalamine granules 63 BEACOPP 63 analgesic efficacy 63 5 fluorouracil leucovorin 63 TAXOTERE ® 63 aminotransferases 63 remission CR 63 TroVax ® 63 thrombocytopenic 63 TACE 63 imatinib Gleevec 63 evaluating tivozanib 63 antithrombotic therapy 63 oral ridaforolimus 63 Decitabine 63 #Gy 63 Cytoxan 63 heavily pretreated patients 63 immunomodulatory agents 63 bendamustine 63 investigational protease inhibitor 63 response CCyR 63 lactate dehydrogenase 63 EOquin TM 63 EndoTAGTM 1 63 squamous histology 63 cinacalcet 63 pharmacologically active isomer 63 Atrasentan 63 clinicopathological features 63 fluoropyrimidine 63 lispro 63 tamoxifen Nolvadex ® 63 administered subcutaneously 63 hemodilution 63 alkylating agent 63 intima media thickness 63 edifoligide 63 huN# DM1 63 ischemic cardiomyopathy 63 ulcer healing 63 antiangiogenic agent 63 INTEGRILIN R 63 refractory AML 63 dexamethasone Decadron 63 paliperidone ER 63 pyrazinamide 63 sorafenib Nexavar ® 63 HBeAg seroconversion 63 novel VDA molecule 63 Secondary endpoints included 63 intact parathyroid hormone 63 opioid analgesia 63 sustained virologic response 63 titration phase 63 Fluorouracil 63 de novo kidney transplant 63 cediranib 63 chemoresistant 63 4mg/kg 63 Newly Diagnosed Multiple Myeloma 63 RECIST criteria 63 EDEMA3 trial 63 interferon alfa 63 mycophenolate mofetil MMF 63 symptomatic intracranial hemorrhage 63 YONDELIS 63 ixabepilone 63 NNRTI resistance 63 etanercept 63 IFN alfa 63 dexpramipexole 63 noninferior 63 ACE inhibitor ramipril 63 MCyR 63 metastatic bone 63 relapsed MCL 63 gemcitabine 63 dasatinib 63 cabazitaxel 63 euthyroid 63 pharmacokinetic PK study 63 adenoma recurrence 63 F FDG PET 63 argatroban 63 demonstrated clinically meaningful 63 antiarrhythmic 63 Retreatment 63 KAPIDEX 63 lenalidomide Revlimid 63 RE LY 63 randomized multicenter Phase III 63 perioperative morbidity 63 BEXXAR Therapeutic Regimen 63 paclitaxel Taxol R 63 chemotherapy docetaxel 63 Dose escalation 63 aspartate aminotransferase 63 renal toxicity 63 HBeAg 63 trastuzumab Herceptin R 63 tapentadol ER 63 Primary endpoints 63 resected pancreatic cancer 63 TAXOTERE R 63 Lenalidomide 63 ventricular remodeling 63 virological response 63 goserelin 63 pulmonary exacerbation 63 piperacillin tazobactam 63 oxaliplatin Eloxatin 63 antiretroviral naïve 63 HER2 expression 63 antiretroviral naive 63 Median survival 63 pretransplant 63 mucosal healing 63 virological failure 62 candesartan cilexetil 62 dose escalation phase 62 metastatic GIST 62 cytotoxic therapy 62 preoperative chemotherapy 62 parathyroidectomy 62 Vascugel ® 62 antibody MAb 62 tumor regression 62 PROSTVAC VF 62 SSc 62 COPAXONE 62 HuMax EGFr 62 liver metastasis 62 pegylated IFN 62 systemic corticosteroid 62 serum phosphate levels 62 forodesine 62 patients evaluable 62 lung metastasis 62 EDARBI 62 NLX P# 62 cerebral vasospasm 62 Gemcitabine 62 metastatic castration resistant 62 Natalizumab 62 hsCRP levels 62 ziprasidone 62 folinic acid 62 erythropoietic 62 virologic failure 62 #mg dose [002] 62 amisulpride 62 tumor resection 62 Alequel 62 ErbB2 positive 62 mTOR inhibitors 62 XL# SAR# 62 Pharmacokinetic studies 62 QTc interval 62 LEP ETU 62 ispinesib administered 62 QT intervals 62 Taxol paclitaxel 62 detectable HCV RNA 62 tumor regressions 62 briakinumab 62 Ceplene/IL-2 62 eculizumab therapy 62 levosimendan 62 peg IFN 62 Median progression 62 dexanabinol 62 platelet inhibitor 62 cyclophosphamide doxorubicin vincristine 62 Randomized trials 62 QD dosing 62 biliary tract cancer 62 mTOR inhibition 62 SPRYCEL ® 62 pharmacodynamic parameters 62 telomerase inhibition 62 TNF inhibitor 62 fosbretabulin 62 Temozolomide 62 nadolol 62 thromboembolic complications 62 CHARM Added 62 antiandrogen 62 thetreatment 62 adjunctive placebo 62 bowel resection 62 Kaplan Meier 62 cardiac toxicity 62 severe exacerbations 62 Capesaris 62 postintervention 62 GnRH agonist 62 PPAR gamma agonist 62 ZD# [001] 62 peginterferon alfa 2b 62 PRADAXA #mg 62 aprepitant 62 dual endothelin receptor antagonist 62 rFSH 62 gemtuzumab ozogamicin 62 dose melphalan 62 angiographic restenosis 62 temozolomide 62 iniparib 62 lactate dehydrogenase LDH 62 intravesical 62 deep venous thromboses 62 tolvaptan 62 cardiac repolarization 62 Cytarabine 62 neratinib 62 ipsilateral stroke 62 hyperalgesia 62 pentoxifylline 62 evaluable 62 echocardiographic parameters 62 Median PFS 62 paroxysmal AF 62 TORISEL 62 cilostazol 62 highly emetogenic 62 HGS# 62 interferon beta therapy 62 plus ribavirin 62 clinically localized prostate 62 aspartate aminotransferase AST 62 lumiliximab 62 Motexafin Gadolinium 62 anagrelide 62 VcMP 62 vincristine doxorubicin 62 protease inhibitor PI 62 Tasigna prolongs 62 protein excretion 62 sustained virological response 62 ER CHOP 62 epoetin alpha 62 coadministration 62 ACTEMRA TM 62 Granulocyte Colony Stimulating Factor 62 Neoadjuvant 62 PKC# 62 favorable pharmacokinetic profile 62 Panzem R NCD 62 MP4OX 62 etoposide 62 unresectable tumors 62 AST ALT 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 acromegalic patients 62 orally administered inhibitor 62 mCRC patients 62 plasma renin activity 62 clinically meaningful reductions 62 neoadjuvant 62 platelet reactivity 62 ximelagatran 62 zalutumumab 62 rapid virologic response 62 IOP lowering 62 CYPHER Stent 62 taxotere 62 bevacizumab Avastin ® 62 diabetic gastroparesis 62 operable breast cancer 62 Teriparatide 62 rufinamide 62 partial remissions 62 tumor shrinkage 62 Glioblastoma Multiforme 62 Patients Receiving 62 phase IIb study 62 LEXIVA r 62 annualized relapse 62 colorectal cancer liver metastases 62 Meets Primary Endpoint 62 beta blocker therapy 62 multivariable analysis 62 evaluable subjects 62 vasopressor 62 alanine aminotransferase ALT 62 caspofungin 62 cetuximab Erbitux 62 Azacitidine 62 divalproex sodium 62 thalidomide dexamethasone 62 mcg kg 62 Camptosar ® 62 Pharmacokinetics PK 62 Elitek 62 phase IIIb 62 metastatic pancreatic 62 lanthanum carbonate 62 postdose 62 imetelstat 62 ORENCIA ® 62 pain palliation 62 denileukin diftitox 62 pharmacokinetics PK 62 unfractionated heparin 62 antimetabolite 62 receptor inhibitor 62 VADT 62 enzastaurin 62 PEGINTRON TM 62 oxycodone CR 62 HMG CoA reductase inhibitors 62 Androxal TM 62 relapsed myeloma 62 cardiovascular hospitalizations 62 Fludara 62 placebo dexamethasone 62 mitoxantrone chemotherapy 62 PEGylated interferon beta 1a 62 NSABP B 62 paclitaxel Taxol ® 62 multivariate Cox 62 evaluating Actimmune 62 glomerular filtration 62 HBeAg positive patients 62 sotalol 62 phase IIb clinical 62 infarct size 62 Vidaza ® 62 pharmacokinetic equivalence 62 CINQUIL 62 corticosteroid dexamethasone 62 NEVO 62 histological subtype 62 dosing cohorts 62 Phase Ib clinical 62 serum phosphorous 62 cannabinor 62 adrenal suppression 62 haematologic 62 abacavir Ziagen 62 postprocedure 62 retinal vein occlusion induced 62 telaprevir dosing 62 C1 INH 62 Forodesine HCl 62 nilotinib 62 hemodialysis patients 62 myocardial reperfusion 62 renoprotective 62 Intravitreal 62 Jevtana 62 Safinamide 62 p = NS 62 durable remissions 62 Target Lesion Revascularization TLR 62 VAPRISOL 62 diabetic kidney 62 HBeAg negative 62 bortezomib 62 refractory chronic lymphocytic 62 INSPIRE Trial Phase III 62 metastatic renal cell carcinoma 62 isoproterenol 62 previously untreated follicular 62 interferon gamma 1b 62 KRAS wild 62 BRIM2 62 SNT-MC#/idebenone 62 inhibitor RG# 62 biochemical recurrence 62 cetuximab Erbitux ® 62 AQ4N 62 atorvastatin #mg 62 TPV r 62 Refractory Hodgkin Lymphoma 62 PEGylated Fab fragment 62 HCV SPRINT 62 pharmacodynamic profile 62 nilotinib Tasigna ® 62 IRX 2 62 IV bisphosphonates 62 EBRT 62 selective modulator 62 NPH insulin 62 budesonide foam 62 Combination therapy 62 LV dysfunction 62 Cimzia TM 62 intracoronary 62 tanespimycin 62 CA4P 62 LHRH agonists 62 pharmacokinetic interactions 62 peginterferon alfa 62 corticosteroid therapy 62 Traficet EN 62 epirubicin cyclophosphamide 62 attain statistical significance 62 Dasatinib 62 infliximab monotherapy 62 Triapine R 62 renal flares 62 Tumor Response 62 saline placebo 61 refractory CLL 61 relapsing remitting MS RRMS 61 perioperative complications 61 anthracycline containing 61 EXJADE 61 DFMO 61 paclitaxel eluting stents 61 TLK# 61 elotuzumab 61 liposomal formulation 61 CBLC# 61 atrioventricular block 61 docetaxel Taxotere 61 sorafenib tablets 61 QTc 61 paroxetine sertraline 61 Carotid Revascularization Endarterectomy vs. 61 receptor tyrosine kinase inhibitor 61 plus octreotide LAR 61 relapsed AML 61 drug zotarolimus 61 bone marrow reticulin deposition 61 EndoTAG TM -1 61 lymphocytosis 61 antihypertensive therapy 61 Unstable Angina 61 APOPTONE 61 torsade de pointes 61 aripiprazole 61 ExTRACT TIMI 61 Hazard Ratio 61 antioxidant supplementation 61 ABC/3TC 61 statin monotherapy 61 posttreatment 61 Capecitabine 61 bicifadine 61 tolterodine 61 CLARITY study 61 Inhaled nitric oxide 61 eptifibatide 61 RLAI 61 renal artery stenting 61 prostate cancer HRPC 61 statistically significant p = 61 Ophena TM 61 CIMZIA R 61 CC genotype 61 Amrubicin 61 HIV RNA 61 oral FTY# 61 ruxolitinib 61 Gliadel Wafer 61 oral levofloxacin 61 underwent surgical resection 61 donepezil Aricept 61 ELOXATIN 61 SERCA2a 61 Interferon beta 1a 61 prospectively stratified 61 Aggrastat ® tirofiban hydrochloride 61 remission induction 61 thrombolytic agents 61 omega interferon 61 ZACTIMA 61 generation purine nucleoside 61 thromboembolic events 61 patients receiving myelosuppressive 61 MVA MUC1 IL2 61 Randomized Evaluation 61 reteplase 61 PD LID 61 uric acid lowering 61 darunavir r 61 FOLFOX 61 colorectal carcinoma 61 invasive aspergillosis 61 REMINYL ® 61 serum aminotransferase levels 61 GORE TAG Device 61 metastatic gastric 61 H. pylori eradication 61 pancreatic adenocarcinoma 61 HBeAg negative patients 61 tocilizumab 61 noninferiority 61 temozolomide TMZ 61 dose cohort 61 oxymorphone ER 61 mcg BID 61 pulmonary exacerbations 61 sunitinib 61 octreotide implant 61 Postoperatively 61 CAMMS# 61 urate lowering 61 Phase Ib II 61 docetaxel prednisone 61 icatibant 61 neoadjuvant chemotherapy 61 tenecteplase 61 intranasal formulation 61 Achieves Primary Endpoint 61 osteoporotic vertebral compression fractures 61 baseline LDH 61 endometrial hyperplasia 61 μmol L 61 EGFR expressing 61 GW# [003] 61 tumor lysis syndrome 61 plasma pharmacokinetics 61 cyclophosphamide Cytoxan 61 lymph node metastasis 61 anthracyclines taxanes 61 Phase #b/#a clinical 61 paraprotein 61 bevacizumab Avastin R 61 Aclidinium 61 CYP#D# inhibitor 61 mg m² 61 distant metastasis 61 TNF blocker therapy 61 lymphadenectomy 61 N acetylcysteine 61 chemotherapeutic regimen 61 prucalopride 61 rFVIII 61 nephrotoxicity 61 PSN# [002] 61 Phase IIIb clinical 61 GRN# 61 tissue oxygenation 61 chronic idiopathic thrombocytopenic purpura 61 hypoperfusion 61 ACCOMPLISH 61 BENICAR HCT 61 Enzastaurin 61 natriuretic peptide 61 endometrial carcinoma 61 adrenalectomy 61 QRS duration 61 serum concentrations 61 daunorubicin 61 lipid altering 61 mg QD 61 fibrinolytic 61 chemoresistance 61 rtPA 61 darunavir ritonavir 61 Phase III randomized controlled 61 rt PA 61 Ocrelizumab